Plaintiffs allege that Novo Nordisks marketing campaign misled consumers by focusing on the benefits of weight loss while downplaying the potential for severe health risks, including intestinal blockages and stomach paralysis
On November 6, 2025, President Trump announced agreements with pharmaceutical manufacturers Eli Lilly and Novo Nordisk to dramatically reduce GLP-1 prices and expand Medicare coverage for obesity
Understanding why hunger feels different can bring clarity, reassurance and a gentler path forward
Clinical trials have shown their efficacy and safety over several years, yet the possibility of long-term adverse effects remains a research focus
During a subcutaneous injection, a short needle is used to inject a drug into the fatty tissue layer between the skin and the muscle, usually in specific areas of the thigh, arm, and abdomen